Back Hepatitis C

Hepatitis C

AASLD 2013: HCV Levels in Semen May Correspond to Blood Viral Load

HIV positive men with higher hepatitis C virus (HCV) RNA levels in their blood during acute infection were more likely to have HCV in their semen as well, which may raise the risk of sexual transmission, researchers reported last month at the 64thAASLD Liver Meeting in Washington, DC.

alt

AbbVie Combo Cures 96% of Treatment-experienced Hepatitis C Patients

A 4-drug regimen containing 3 AbbVie direct-acting antivirals plus ribavirin produced sustained virological response in 96% of chronic hepatitis C patients without cirrhosis who were previously treated unsuccessfully with pegylated interferon and ribavirin, with similar response rates for HCV genotypes 1a and 1b, the company announced.

alt

Injection Drug Users Who Know They Have Hepatitis C Practice "Sero-Sharing"

People who inject drugs who know they are hepatitis C virus (HCV) positive are more likely to share syringes and injection equipment with others who are also infected, and less likely to do so with people who are HCV negative or unknown -- the equivalent of sexual "serosorting," according to a report in the December 15, 2013, Journal of Infectious Diseases.

alt

Hepatitis C Virus Can Live on Surfaces for Up to 6 Weeks

Hepatitis C virus (HCV) in dried droplets of blood or plasma can remain infectious on uncovered surfaces at temperatures of 4° or 22° C (39° or 72° F) for up to 6 weeks, resulting in potential for transmission in healthcare settings or during injection drug preparation, researchers reported in the November 23, 2013, advance edition of the Journal of Infectious Diseases.

alt

AASLD 2013: MK-5172 + Ribavirin Works Well for People with Hepatitis C Genotype 1b

An interferon-free regimen consisting of Merck's next-generation hepatitis C virus (HCV) protease inhibitor MK-5172 plus ribavirin led to high rates of viral suppression and promising early cure rates for patients with HCV subtype 1b, according to a poster presented at the 64thAASLD Liver Meeting last month in Washington, DC.

alt

FDA Approves Sofosbuvir (Sovaldi) for Hepatitis C Genotypes 1, 2, 3, and 4

The U.S. Food and Drug Administration on Friday approved the first hepatitis C virus (HCV) polymerase inhibitor, sofosbuvir, to be marketed by Gilead Sciences under the brand name Sovaldi. Sofosbuvir was approved for use with ribavirin for people with HCV genotypes 2 or 3 -- making it the first-ever interferon-free hepatitis C treatment -- and in combination with pegylated interferon/ribavirin for people with harder-to-treat HCV genotypes 1 or 4.

alt

AASLD 2013: Sofosbuvir + Ribavirin Effective Against Hepatitis C Genotype 4

A dual oral regimen of sofosbuvir plus ribavirin taken for 24 weeks led to an early cure at 4 weeks post-treatment for difficult-to-treat patients with hepatitis C virus (HCV) genotype 4, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC.

alt

Sofosbuvir/Ledipasvir Cures More than 90% of Genotype 1 Hepatitis C

Gilead Sciences this week announced sustained virological response rates from the Phase 3 ION trials testing a combination pill containing its newly approved HCV polymerase inhibitor sofosbuvir (Sovaldi) plus the NS5A inhibitor ledipasvir. Across the 3 studies, sofosbuvir/ledipasvir taken for 8 or 12 weeks cured more than 90% of treatment-naive and treatment-experienced genotype 1 patients.

alt

AASLD 2013: Faldaprevir Triple Therapy Effective Across Patient Subgroups

The experimental hepatitis C virus (HCV) protease inhibitor faldaprevir in combination with pegylated interferon and ribavirin was effective across a range of subgroups of patients with genotype 1 infection -- including prior relapsers and non-responders -- in the STARTVerso clinical trials program, according to research presented at the recent AASLD Liver Meeting in Washington, DC.

alt